Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1242

Similar articles for PubMed (Select 17996927)

1.

The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS.

Gynecol Oncol. 2008 Feb;108(2):287-92. Epub 2007 Nov 13.

PMID:
17996927
2.

The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.

Zivanovic O, Sima CS, Iasonos A, Hoskins WJ, Pingle PR, Leitao MM Jr, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS.

Gynecol Oncol. 2010 Mar;116(3):351-7. doi: 10.1016/j.ygyno.2009.11.022.

PMID:
20022092
3.

Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, DeMatteo R, Poynor EA, Abu-Rustum NR, Barakat RR.

Gynecol Oncol. 2004 Sep;94(3):650-4.

PMID:
15350354
4.

What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR.

Gynecol Oncol. 2006 Nov;103(2):559-64. Epub 2006 May 22.

PMID:
16714056
5.

The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.

Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, Jarnagin WR, DeMatteo RP, D'Angelica MI, Barakat RR, Chi DS.

Gynecol Oncol. 2006 Dec;103(3):1083-90. Epub 2006 Aug 4.

PMID:
16890277
6.

A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.

Chi DS, Zivanovic O, Palayekar MJ, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Leitao MM, Brown CL, Barakat RR.

Gynecol Oncol. 2009 Jan;112(1):6-10. doi: 10.1016/j.ygyno.2008.10.010.

PMID:
19100916
7.

The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.

Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J, Gardner GJ, Leitao MM Jr, Levine DA, Sonoda Y, Abu-Rustum NR, Brown CL, Barakat RR.

Gynecol Oncol. 2010 Oct;119(1):38-42. doi: 10.1016/j.ygyno.2010.05.031. Epub 2010 Jul 6.

PMID:
20609464
8.

Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Shih KK, Chi DS, Barakat RR, Leitao MM Jr.

Gynecol Oncol. 2010 Mar;116(3):364-9. doi: 10.1016/j.ygyno.2009.10.047. Epub 2009 Nov 7.

PMID:
19897231
9.

Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience.

Peiretti M, Zanagnolo V, Aletti GD, Bocciolone L, Colombo N, Landoni F, Minig L, Biffi R, Radice D, Maggioni A.

Gynecol Oncol. 2010 Nov;119(2):259-64. doi: 10.1016/j.ygyno.2010.07.032. Epub 2010 Aug 25.

PMID:
20800269
10.

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).

Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR.

Gynecol Oncol. 2012 Jan;124(1):10-4. doi: 10.1016/j.ygyno.2011.08.014. Epub 2011 Sep 13.

PMID:
21917306
11.

Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.

Luyckx M, Leblanc E, Filleron T, Morice P, Darai E, Classe JM, Ferron G, Stoeckle E, Pomel C, Vinet B, Chereau E, Bergzoll C, Querleu D.

Int J Gynecol Cancer. 2012 Oct;22(8):1337-43.

PMID:
22964527
12.

Characteristics and management of diaphragm involvement in patients with primary advanced-stage ovarian, fallopian tube, or peritoneal cancer.

Einenkel J, Ott R, Handzel R, Braumann UD, Horn LC.

Int J Gynecol Cancer. 2009 Oct;19(7):1288-97. doi: 10.1111/IGC.0b013e3181a3a833.

PMID:
19823067
13.

Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.

Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR.

Gynecol Oncol. 2009 Jul;114(1):26-31. doi: 10.1016/j.ygyno.2009.03.018. Epub 2009 Apr 23.

PMID:
19395008
14.

Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer.

Black D, Iasonos A, Ahmed H, Chi DS, Barakat RR, Abu-Rustum NR.

Gynecol Oncol. 2007 Oct;107(1):66-70. Epub 2007 Jul 5.

PMID:
17614125
15.
16.

Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series.

Shih KK, Chi DS, Barakat RR, Leitao MM Jr.

Gynecol Oncol. 2010 May;117(2):330-5. doi: 10.1016/j.ygyno.2010.01.046. Epub 2010 Feb 26.

PMID:
20189234
17.

Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller.

Chi DS, Barlin JN, Ramirez PT, Levenback CF, Mironov S, Sarasohn DM, Iyer RB, Dao F, Hricak H, Barakat RR.

Int J Gynecol Cancer. 2010 Apr;20(3):353-7. doi: 10.1111/IGC.0b013e3181d09fd6.

PMID:
20375796
18.

The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy.

Kapp KS, Kapp DS, Poschauko J, St├╝cklschweiger GF, Hackl A, Pickel H, Petru E, Winter R.

Gynecol Oncol. 1999 Sep;74(3):400-7.

PMID:
10479500
19.
20.

Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.

Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY.

Gynecol Oncol. 1999 Mar;72(3):278-87.

PMID:
10053096
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk